See every side of every news story
Published loading...Updated

Economic analysis supports cost-effectiveness of Guardian monitoring system in high-risk acute coronary syndromes - Cardiovascular News

Summary by Cardiovascular News
Avertix Medical has announced the publication of new data on the cost-effectiveness of its Guardian system in high-risk acute coronary syndrome (ACS) patients. The Guardian system is a US Food and Drug Administration (FDA)-approved heart attack warning system to improve long-term management and outcomes of high-risk coronary disease. The study, conducted by researchers from Duke Clinical Research Institute (Durham, USA), published in Future Card…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cardiovascular News broke the news in on Friday, February 14, 2025.
Sources are mostly out of (0)